Deuterated VX-661 Metabolic Stability via Kinetic Isotope Effect
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medicines often suffer from poor absorption, distribution, metabolism, and excretion (ADME) properties, leading to rapid drug clearance and the formation of toxic metabolites, which can result in suboptimal treatment efficacy and adverse effects, and existing strategies like CYP enzyme inhibition are not satisfactory due to their side effects and complexities.
Innovation Solution
Development of deuterated forms of VX-661, a deltaF508-cystic fibrosis transmembrane conductance regulator corrector, to improve metabolic properties by slowing down CYP-mediated metabolism and reducing undesirable metabolite formation, thereby enhancing the drug's efficacy and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If deuterium substitution is applied to slow metabolism, then drug clearance is reduced and half-life is extended, but metabolic rate may increase in certain cases
Solution Approach 1:
The patent applies deuterium substitution at specific positions in the VX-661 molecule to change the kinetic isotope effect parameters. By replacing hydrogen with deuterium at metabolically labile positions, the C-H bond strength is increased, slowing down CYP-mediated metabolism and extending drug half-life without affecting overall metabolic rate
2Duration of action of stationary object
If CYP enzyme inhibitors are co-administered to reduce drug clearance, then drug half-life is extended, but adverse effects increase and treatment complexity increases
Solution Approach 1:
The patent extracts the metabolic modification function directly into the drug molecule itself through deuterium substitution, rather than relying on external CYP inhibitors. This eliminates the need for co-administration of separate inhibitor drugs, reducing pill burden and adverse effects while achieving the desired extension of drug half-life
3Duration of action of stationary object
If CYP enzyme inhibitors are co-administered to reduce drug clearance, then drug half-life is extended, but treatment complexity increases
Solution Approach 1:
The patent combines the therapeutic function and the metabolic stability function into a single deuterated drug molecule. The deuterium substitution is integrated directly into the VX-661 structure, merging what would otherwise require separate drugs (the CFTR corrector and the CYP inhibitor) into one unified treatment regimen
4Object-affected harmful factors
If deuterium substitution is applied to reduce toxic metabolite formation, then safety is improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies deuterium substitution selectively at specific positions in the VX-661 molecule where metabolism occurs, rather than throughout the entire molecule. This localized approach targets the metabolically labile positions to reduce toxic metabolite formation while minimizing the complexity of manufacturing compared to full deuteration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The deuterated forms of VX-661 effectively address the issues of rapid drug clearance and toxic metabolite formation, potentially offering improved therapeutic outcomes with enhanced safety and tolerability for cystic fibrosis treatment.
Implementation Method 1
Deuterium is a safe, stable, non-radioactive isotope of hydrogen. Compared to hydrogen, deuterium forms stronger bonds with carbon. In select cases, the increased bond strength imparted by deuterium can positively impact the ADME properties of a drug
Data Source
AI summary
This invention relates to novel, deuterated forms of VX-661 and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating cystic fibrosis.